Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

Abstract Number: 0630 • ACR Convergence 2021
Telemedicine in Rheumatology Care: A Systematic Review
Lesley Jackson¹, Timothy Edgil², Brittany Hill³, Catherine H. Smith⁴, Jasvinder Singh¹ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Brookwood Baptist Health, Leeds, AL, ⁴Lister Hill Library of the Health Sciences, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Coronavirus disease 2019 (COVID-19) pandemic led to a dramatic uptake of telemedicine in rheumatology. Given the impact of the pandemic on care delivery, we…
Abstract Number: 1083 • ACR Convergence 2021
Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey
Samira Nazzar Romero¹, Lakshmi Moorthy², Jennifer Tousseau³, Sivia Lapidus⁴, Mariana Correia Marques⁵, Leanne Mansfield⁶, Marinka Twilt⁷, Grant Schulert⁸, Maria Gutierrez⁹, Saskya Angevare¹⁰, Fatma Dedeoglu¹¹ and Karen Durrant¹², ¹University of California Los Angeles, Los Angeles, CA, ²Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Autoinflamamtory Alliance, Lincoln, CA, ⁴The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, ⁵UPMC Children`s Hospital of Pittsburgh, Pittsburgh, PA, ⁶Hospital for Special Surgery, New York, NY, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹John's Hopkins, Baltimore, MD, ¹⁰Autoinflammatory Alliance / Kaisz / ENCA as patient organizations, Amersfoort, Netherlands, ¹¹Boston Children's Hospital, Boston, MA, ¹²Autoinflammatory Alliance, San Francisco, CA
Background/Purpose: The exaggerated inflammatory responses to the SARS-CoV-2 virus and the paucity of data on COVID-19 infection risk in systemic autoinflammatory disease (SAID) patients posed…
Abstract Number: 1084 • ACR Convergence 2021
COVID-19 Among Patients with Inflammatory Arthropathies Participating in the RHUMADATA Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Loïc Choquette Sauvageau¹, Boulos Haraoui¹, Isabelle Ferdinand¹, Frédéric Massicotte¹, Valerie Nadon¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal³, ¹Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ³Institut de Rhumatologie de Montréal, Saint-Lambert, QC, Canada
Background/Purpose: The COVID-19 pandemic has hit the world since 2019. The province of Québec in Canada has not escaped this plague. Our goal is to…
Abstract Number: 1088 • ACR Convergence 2021
The Association Between Anti-Type Ⅱ Collagen Antibodies at the Time of Diagnosis and Recurrence in Relapsing Polychondritis
Osamu Iri, Keisuke Nishimura, Daisuke Waki, Kohei Yo, Ryuta Inaba, Shintaro Yamamoto, Kaoru Mizukawa, Tomohiro Yoshida, Hiroyuki Murabe and Toshihiko Yokota, Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Serum titers of anti-type Ⅱ collagen (anti-CⅡ) antibodies were reported to rise at the recurrence of relapsing polychondritis (RP). It remains to be identified…
Abstract Number: 1455 • ACR Convergence 2021
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
Jun Shimizu¹, Sueshige Wakisaka¹, Tomoko Suzuki¹ and Noboru Suzuki², ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan
Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disorder that affects cartilage of ears, nose, joints, and respiratory tract. The inflammation often spreads to eyes, cardiovascular…
Abstract Number: 1518 • ACR Convergence 2021
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Pankti Reid¹, David Liew², Rajshi Akruwala³, Anne Bass⁴ and Karmela Kim Chan⁵, ¹University of Chicago Medical Center, Chicago, IL, ²Austin Health, Heidelberg, Australia, ³SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 1544 • ACR Convergence 2021
Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
Sofia Carvalho Barreira¹, Ana Rita Cruz-Machado¹, Matilde Bandeira¹, Catarina Duarte², Maria Rato³, Bruno Fernandes⁴, Salomé Garcia³, Filipe Pinheiro³, Miguel Bernardes³, Nathalie Madeira⁵, Cláudia Miguel⁵, Rita Torres⁶, Ana Bento Silva⁶, Jorge Pestana⁷, Diogo Almeida⁸, Carolina Mazeda⁹, Filipe Cunha Santos¹⁰, Patrícia Pinto¹¹, Marlene Sousa¹², Hugo Parente¹³, Graca Sequeira¹⁴, Maria José Santos⁷, João Eurico Fonseca¹⁵ and Vasco C Romão¹⁵, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁵Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, ⁶Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁷Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁸Rheumatology Department, Hospital de Braga, Braga, ⁹Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁰Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹¹Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Gaia, Portugal, ¹²Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹³Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Background/Purpose: Since the beginning of the COVID-19 pandemic, some studies have addressed risk factors for severe forms of the disease in patients with rheumatic diseases.…
Abstract Number: 1549 • ACR Convergence 2021
Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
Michael Grant¹, Matas Orentas², Sobia Hassan¹, Sonali Khandelwal¹, Donyea Moore³ and Najia Shakoor¹, ¹Rush University, Chicago, IL, ²RUMC, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: The COVID-19 pandemic has been particularly concerning for patients with rheumatologic conditions because they are potentially predisposed to more severe outcomes. Studies have suggested…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 1558 • ACR Convergence 2021
Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study
Diana Villacis Nunez¹, Kaitlin Jones², Lucie Fan³, Whitney Moore², Aysha Jabbar², Matthew Oster⁴, Preeti Jaggi¹ and Sampath Prahalad⁵, ¹Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Herman Tam¹, Alison Lopez², Mona Patel², Jonathan Rayment³, Lori Tucker⁴ and Catherine Biggs⁵, ¹Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, ³British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵[email protected], Vancouver, BC, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…
Abstract Number: 0099 • ACR Convergence 2021
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Kurt de Vlam¹, Jeroen Geldhof², Marie Truyens³, Joao Sabino⁴, Marc ferrante⁴, Jo Lambert³, Hilde lapeere³, Tom hillary⁴, an Van Laethem⁴, Triana Lobaton³, severine vermeire⁴, Barbara Neerinckx¹ and Patrick Verschueren⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²University Hospital Gent, Gent, Belgium, ³university hospital gent, gent, ⁴university hospitals leuven, leuven, ⁵University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Lauren Covert¹, Mara Becker², Rebecca Sadun¹ and Heather Van Mater¹, ¹Duke University, Durham, NC, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].